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ABSTRACT
VEGFR-2 and P2X7 receptor (P2X7R) have been described to stimulate the 
angiogenesis and inflammatory processes of prostate cancer. The present study has 
been performed to investigate the genetic interactions among VEGFR-2 and P2X7R 
SNPs and their correlation with overall survival (OS) in a population of metastatic 
prostate cancer patients. Analyses were performed on germline DNA obtained from 
blood samples and SNPs were investigated by real-time PCR technique. The survival 
dimensionality reduction (SDR) methodology was applied to investigate the genetic 
interaction between SNPs. One hundred patients were enrolled. The SDR software 
provided two genetic interaction profiles consisting of the combination between 
specific VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) 
genotypes. The median OS was 126 months (95% CI, 115.94–152.96) and 65.65 
months (95% CI, 52.95–76.53) for the favorable and the unfavorable genetic profile, 
respectively (p < 0.0001). The genetic statistical interaction between VEGFR-2 
(rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes may identify 
a population of prostate cancer patients with a better prognosis.
INTRODUCTION
The prostate cancer progression has been related to 
many factors such as inflammation [1] and the so-called 
angiogenic switch that implies enhanced angiogenesis, 
characterized by high vascular endothelial growth 
factor (VEGF) and VEGF receptor (VEGFR) levels 
[2]. Although significance of inflammation in cancer 
progression is still a debated issue, some evidences suggest 
pathways directed to connection between inflammation 
and cancer evolution [3]. Indeed, the proliferative 
inflammatory atrophy has been proposed as possible 
precursor of prostatic intraepithelial neoplasm. Since 
inflammatory microenvironment releases growth factors 
(such as VEGF) and cytokines, proangiogenic factors may 
influence the activation of the vascular endothelial cells 
and signal transduction in these cells [3]. Angiogenesis 
is an important step in the development of cancer and is 
necessary for primary tumor growth, invasiveness, and 
metastasis. This neovessel formation is stimulated by 
different proangiogenic factors secreted by cells pertaining 
to the tumor itself and to its microenvironment [4]. 
Kinase insert domain receptor (KDR or VEGFR-2) is the 
principal receptor that promotes the pro-angiogenic action 
of vascular endothelial growth factor and is recognized as 
the main target of anti-angiogenic therapies.
The extracellular signalling molecule ATP (eATP) 
has been shown to mediate various biological functions 
including synaptic neurotransmission, nociception, smooth 
muscle contraction, and endocrine secretion [5, 6]. eATP 
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acts via specific P2 receptors, ion-gated channels classified 
into ionotropic (P2X) and metabotropic (P2Y) subtypes. In 
the last fifteen years, attention has been paid to the complex 
relationship between purinergic signal and cancer [5, 7]. 
Among the various ATP-sensitive receptors, the P2X
7
 
receptor (P2X
7
R) has attracted our attention as potential 
mediator of the cellular processes described above, 
especially in prostatic carcinoma, where an increased 
P2X
7
R expression has been reported, irrespective of 
Gleason grade or patient age [8]. Moreover, Ravenna and 
colleagues have suggested that an up-regulation of P2X
7
R 
in bioptic specimens of prostate cancer might trigger the 
generation of other pro-inflammatory molecules through 
NF-kB activation [9].
The gene encoding for P2X
7
R, located at 
chromosome position 12q24, is highly polymorphic. 
Several loss-of-function polymorphisms may alter the 
normal trafficking and activity of the receptor [10, 11]. 
The VEGFR-2 gene is located on chromosome 4q11-q12. 
Several single-nucleotide polymorphisms (SNPs) 
have been described in the VEGFR-2 gene, some of 
which able to increase/decrease gene expression itself, 
circulating levels of soluble VEGFR-2 and the VEGF 
binding efficiency to the receptor [12]. Many authors 
have pointed out the unlikeliness that just a SNP can 
predict the prognosis or the therapeutic response to drugs, 
mainly due to the complexity of the involved biological 
systems [4, 13, 14]. Therefore, the prognosis of advanced 
prostate cancer could depend on many factors, likely 
interacting with a complex genetic background. Indeed, 
the effect of a SNP on its corresponding gene may be 
the result of an interaction between the polymorphisms 
of other functionally linked genes. This phenomenon is 
defined as epistasis [15, 16]. Gene–gene interactions are 
an essential part of gene regulation, signal transduction, 
biochemical networks, and homeostatic, developmental, 
and physiological pathways. Indeed, the epistasis 
phenomenon involves DNA sequence variations, 
biomolecules and their physical interactions giving rise 
to a phenotype at a particular time point [17]. Therefore, 
the current approach of correlating the prostate cancer 
prognosis to a single SNP may be replaced by a genetic 
analysis of the interaction between SNPs. The aim of 
this new approach should be to unveil a genetic profile 
with a reliable prognostic value. Beretta and colleagues 
have created and validated a methodology called survival 
dimensionality reduction (SDR), an innovative approach 
to detect epistasis in presence of right-censored data, to 
identify a genetic profile with the ability to predict a better 
survival of patients [18].
Based on these hypotheses, we conducted 
a retrospective study to assess the ability of SDR 
methodology to identify a genetic profile of VEGFR-2 and 
P2X7R polymorphisms associated to the overall survival 
(OS) in an unselected population of prostate cancer 
patients.
RESULTS
One-hundred patients with histological diagnosis 
of prostate adenocarcinoma were enrolled into the 
study (Table 1). Ninety-three patients were treated with 
chemotherapy (45 patients received more than 2 lines 
of chemotherapy) such as docetaxel, estramustine, 
mitoxantrone, cyclophosphamide, and vinorelbine. 
Radiotherapy was administered in 6 patients, whereas 
95 patients received androgen deprivation therapy soon 
after the prostate cancer diagnosis or at the time of the 
metastatic disease. Thirty-four patients underwent surgery.
In Table 2 the associations of clinical and 
pathological characteristics with OS are reported. The 
univariate Cox regression analysis confirmed the expected 
role of the Gleason score, the ECOG PS and the number of 
metastatic sites in determining the prognosis of this group 
of patients.
Details about genotypes and allele frequencies of all 
SNPs in the studied population are reported in Table 3; all 
the SNPs were in HWE. None of the single SNPs showed 
a statistically significant association in univariate Cox 
regression analysis, either under an additive, dominant 
or recessive model as illustrated in Table 4, with the 
only exception of VEGFR-2 rs2305948 that reaches the 
significance threshold in the dominant model. However, 
this statistically significant association is certainly a false-
positive result due to the large confidence interval and the 
occurrence of just one TT case. Furthermore, the haplotype 
analysis of the two genetic regions did not reveal any 
significant association in univariate Cox regression model 
and Kaplan Meier curves (Supplementary Figure 1).
The SDR analysis revealed a genetic interaction 
profile, consisting of the combination between specific 
VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, 
rs208294) genotypes, significantly correlated with OS. 
Table SDR model (Table 5) shows the full analysis 
conducted by the SDR algorithm in our datasets. Cross-
validation prevented over-fitting as the minimum test-IBS 
(0.1689) was observed for the interaction model, which 
was therefore chosen as the best epistatic model (i.e. the 
4-way SDR model). This model was highly significant 
at the 0.05 threshold after 1000-fold permutation testing 
(p < 0.001). In particular, two genetic profiles were 
identified in patients, as reported in the genetic model table 
(Table 6). The favorable genetic profile was associated with 
a greater OS benefit whereas the unfavorable one with a 
lower OS in the enrolled patients, as shown in Figure 1. 
Indeed, after a median follow-up of 74+ months (range 
14.6 - 231.7+ months), median OS of the enrolled patients 
was 98.9 months (Figure 1A; 95% CI, 77.38–117.36). 
Notably, the median OS for the favorable genetic profile 
was 126 months (Figure 1B; 95% CI, 115.94–152.96 
months) vs. the 65.65 months of the unfavorable genetic 
profile (95%CI, 52.95–76.53 months; p < 0.0001, log-rank 
test; Figure 1B). Moreover, the Supplementary Figure 2 
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Table 1: Patients Characteristics (n = 100)
N° %
Age
Median 70.5
Range 48–91
ECOG Performance Status
0 71 71
1 22 22
2 5 5
Not available 2 2
Metastatic Disease at the Diagnosis
Yes 44 44
No 51 51
Not available 5 5
Sites of Metastatic Disease at the Diagnosis
Bone and Nodes 7 7
Bone 31 31
Nodes 6 6
Not available 5 5
Hormonal Manipulations
Yes 95 95
No 5 5
Surgery 34 34
Radiotherapy 6 6
Chemotherapy
Yes 93 93
No 5 5
Not available 2 2
Number of Lines of Chemotherapy
1 24 24
≥ 2 67 67
Not available 2 2
Serum PSA at the Diagnosis
Median (ng/ml) 99
Range 2.36–5307
Gleason Score at the Diagnosis
< 7 12 12
≥ 7 56 56
Not available 32 32
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also shows the median OS of favorable and unfavorable 
profiles analyzed by the 3-way SDR analysis. The Cox 
proportional hazards model, performed to assess the 
adjusted hazard ratio for the OS of the favorable genetic 
profile, showed a value of 0.29 (95%CI, 0.15–0.56; 
p = 0.0001; Table 7). Supplementary Table 1 shows the 
same multivariate Cox regression model including also the 
variables “therapy” and “metastases sites at the diagnosis” 
that resulted not significant at the univariate analysis, 
confirming the lack of influence, in our model, of these two 
variables on OS. Of note, the probability of an estimated 
2-year survival rate was 98% (95% CI, 87–99) in the 
favorable genetic profile and 92% (95% CI, 78–97) in the 
unfavorable genetic profile; the estimated 3-year survival 
was 96% (95% CI, 85–99) and 82% (95% CI, 66–91), 
respectively. Supplementary Table 2 shows the patient’s 
characteristics of both favorable and unfavorable groups. 
No differences were noted with the exception of the 
number of metastases sites at the diagnosis. Anyway, this 
variable was used in multivariate Cox regression to obtain 
an adjusted model (see Supplementary Table 1). However, 
this analysis confirms that the MTS sites at diagnosis, 
at least in our model, did not influence significantly the 
difference in OS between the two groups.
DISCUSSION
Prostate carcinoma is still a leading cause of morbidity 
and mortality in developed countries, and the expected 
number of cancer cases in the next 15 years will increase by 
> 20% [19]. Localized cancers are usually treated with radical 
prostatectomy or radiation, while for more advanced cancers, 
either recurred or metastasized, the gold standard treatment is 
androgen ablation therapy, followed by the administration of 
chemotherapeutic drugs (e.g. docetaxel) [20].
The identification of biomarkers able to identify 
patients with the best prognosis is urgently needed to 
better define the proper therapeutic approach in the 
management of this disease. In the present analysis, we 
have applied the SDR methodology for identifying a 
genetic profile consisting of the combination between 
specific VEGFR-2 (rs2071559, rs11133360) and P2X7R 
(rs3751143, rs208294) genotypes associated with a 
greater OS as compared to that observed in the whole 
study population, in an unselected population of patients 
with prostate cancer. Among several loss-of-function 
SNPs of the P2X
7
R gene that may alter the normal 
trafficking [21] and activity of the receptor, the rs3751143 
polymorphism has been associated to the familial form of 
chronic lymphocytic leukemia [22] and to the follicular 
variant of papillary thyroid cancer [23]. On the other hand, 
the polymorphism rs208294, leading the substitution of 
histidine for tyrosine at position 155 (H155Y) localized 
in P2X
7
R ectodomain, causes a gain of function of the 
receptor and it has been linked with human chronic 
lymphocytic leukemia lymphocytes [24]. Tumor formed 
by K562 cells transfected for a new mutation (A559-to-G 
substitution) showed a proliferative advantage and higher 
expression of VEGF and MCP1 [25], and haplotypes of 
the P2X7R containing the rs1718119 polymorphism have 
been linked to an enhanced IL-1β secretion [10]. The 
association between the VEGFR-2 SNPs and susceptibility 
or prognosis in several different types of cancers, such as 
renal cell carcinoma, colorectal cancer, hepatocellular 
carcinoma and glioblastoma, has been studied [26–29]. 
The rs2071559 G > A SNP has been reported to alter the 
structure of the binding site in VEGFR-2 gene promoter 
region for transcriptional factor E2F, with a consequent 
decrease of receptor expression, whereas the exonic 
polymorphisms rs1870377 and rs2305948 (in exon 11 and 
exon 7, respectively) resulted in a significant reduction 
of the VEGF binding efficiency to VEGFR-2 [12]. 
Moreover, Glubb and colleagues found that the rs1870377 
T > A increases VEGFR-2 protein phosphorylation, thus 
resulting in an increased microvessel density in lung 
cancer tumor tissues [30].
Table 2: Association between clinical and pathological characteristics with overall survival in the 
whole study cohort
Variables HR p 95%CI
Age 0.99 0.88 0.96 – 1.03
ECOG PS 1.89 0.009 1.17 – 3.06
PSA at the diagnosis 1.018 0.366 0.98 – 1.06
Gleason Score 3.59 0.019 1.23 – 10.44
MTS sites at the diagnosis 1.51 0.061 0.98 – 2.32
Therapy 1.39 0.184 0.85 – 2.27
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval; MTS, 
metastases; PSA, prostate-specific antigen. ECOG PS and MTS were analysed as continuous variable. Gleason Score 
represents the risk difference between patients with <7 (reference) and ≥7. Therapy represents patients who received 
chemotherapy (none, 1 and ≥ 2 lines) and hormonal treatment between diagnosis and metastasis period.
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In our study we firstly associated each individual 
SNP with OS, but no association between each 
polymorphism and OS was found with the only exception 
of VEGFR-2 rs2305948, a false-positive result due to the 
large confidence interval and the occurrence of just one TT 
case. As demonstrated by the epistasis phenomenon, the 
effects of a single SNP can disseminate through numerous 
gene–gene interactions, determining multiple phenotypes; 
thus, we think that the current approach of correlating the 
prognosis to just one SNP should be reconsidered and 
replaced by a genetic analysis of the interaction among 
SNPs. For these reasons, we decided to apply the more 
complex SDR methodology to investigate the interaction 
between germline SNPs, in order to identify a possible 
genetic profile associated with the greater OS probability 
in this unselected population of patients carrying prostate 
cancer (Table 1 and 5). The analyses conducted in 
this population revealed a genetic interaction profile, 
consisting of the combination between specific VEGFR-2 
(rs2071559, rs11133360) and P2X7R (rs3751143, 
rs208294) genotypes, associated with OS. Particularly, 
two genetic profiles were identified in patients, as 
reported in Table 6. The first column was associated with 
a greater OS benefit and the second one with a lower OS, 
respectively. Because of the connections within biological 
pathways, the effects of a single mutation can extend 
through thousands of gene–gene interactions, resulting in 
multiple phenotypes [31]. In our study we demonstrated, 
through the SDR methodology, a never previously shown 
statistically significant interaction between P2X7R and 
VEGFR-2 gene SNPs that potentially relates to prognosis 
of prostate cancer patients.
Genetic information impacts phenotype through 
a hierarchy of proteins that are involved in biological 
processes ranging from transcription to physiological 
homeostasis. Physical interactions among proteins 
and other biomolecules and their impact on phenotype 
are the main components of biological epistasis [32]. 
Biological epistasis occurs at the level of the single patient 
and involves DNA sequence variations, biomolecules 
and their physical interactions determining a particular 
phenotype for that single individual. Instead, statistical 
epistasis is a population event that is made possible by 
interindividual variability in genotypes, biomolecules and 
in their physical interactions [32]. Thus, the differences 
in biological epistasis among individuals in a population 
give rise to statistical epistasis [32]. Evidently, making 
both hypotheses or conclusions about biological function 
and causation from statistical epistasis results in patients 
will always balk in a challenge, unless relevant molecular 
information has been also acquired [33]. However, SDR or 
multifactor dimensionality reduction (MDR) methodology 
[34] has been applied to detect gene-gene interactions for 
several clinical phenotypes, and it may provide means 
Table 3: Polymorphisms, genotypes, allele frequencies and Hardy-Weinberg Equilibrium (HWE)
ID Gene TaqMan SNPgenotyping 
assays
genotype N allele N % HWE p-
value
rs2071559 VEGFR-2 C__15869271_10 AA 29 A 107 0.54 0.8435
AG 49 G 93 0.46
GG 22
rs2305948 VEGFR-2 C__22271999_20 CC 89 C 188 0.94 0.2956
CT 10 T 12 0.06
TT 1
rs1870377 VEGFR-2 C__11895315_20 TT 72 T 169 0.84 0.7
AT 25 A 31 0.16
AA 3
rs11133360 VEGFR-2 C__26111278_10 TT 30 T 110 0.55 1
CT 50 C 90 0.45
CC 20
rs3751143 P2X7R C__27495274_10 AA 60 A 150 0.75 0.0589
AC 30 C 50 0.25
CC 10
rs208294 P2X7R C___3019032_1_ CC 29 C 106 0.53 0.6926
CT 48 T 94 0.47
TT 23
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to find new hypotheses for further testing about epistatic 
interactions in genetic data also in prostate cancer. As an 
example, the interaction between VEGF 2482T and VEGFR 
IVS6 + 54 loci suggests that the inheritance of VEGF and 
VEGFR IVS6 + 54 sequence variants may jointly modify 
prostate cancer susceptibility through their influence on 
angiogenesis [35]. Whilst it is difficult to explain the 
biological meaning of our statistical epistatic data, it should 
be noted that several data support a possible link between 
P2X7R and VEGFR-2 in tumor physiopathology. Although 
at a first glance the two genes, and, consequently, the two 
receptors have completely different activities and signaling 
pathways, it is not surprising that P2X
7
R and VEGFR-2 
share more than a simple biological connection. In fact, it 
has been demonstrated that the modulation of angiogenesis 
exerted by eATP through endothelial P2Y receptors can 
stimulate angiogenic properties such as endothelial cell 
migration and vascular permeability [36, 37]; moreover 
activated P2Y
2
 receptors can transactivate VEGFR-2, 
suggesting a direct link between extracellular nucleotide 
regulation and growth factor signaling [38]. Interestingly, 
Wei and colleagues [39] demonstrated that the chronic 
exposure of C6 glioma cells to 2′,3′-(benzoyl-4-benzoyl)-
ATP (BzATP), a selective P2X
7
R agonist, enhanced the 
expression of pro-inflammatory and angiogenic factors, 
including IL-8 and VEGF, suggesting a link between the 
receptor activation, inflammation, increased angiogenesis 
and tumor cell migration. Furthermore, P2X
7
R-expressing 
Table 4: Association between each polymorphism and overall survival (univariate Cox regression 
model) A p value < 0.0083 was defined as statistically significant (Bonferroni’s correction). *, the statistically 
significant association is a false-positive result due to the large confidence interval and the occurrence of only 
one TT case
Additive model Dominant model Recessive model
ID Gene gen otype N HR p 95%CI gen otype N HR p 95%CI gen otype N HR P 95%CI
rs 2071559 VEGFR-2 AA 29 1 - - AA 29 1 - -
AG 49 1.06 0.85
0.56 – 
1.99
AA/AG 78 1 - -
GG 22 0.97 0.94 0.46 – 
2.04
GG 22 0.93 0.83 0.49 – 
1.75
AG/GG 71 1.03 0.91
0.57 – 
1.86
rs 2305948 VEGFR-2 CC 89 1 – – CC 89 1 – –
CT 10 0.7 0.59 0.47 – 
3.7
CC/CT 99 1 – –
TT 1 22.3 0.006* 2.5 – 
200.5
TT 1 21.7 0.006* 2.42 – 
194.1
CT/TT 11 1.63 0.3 0.64 – 
4.1
rs 1870377 VEGFR-2 TT 72 1 – – TT 72 1 – –
AT 25 1.34 0.37
0.7 – 
2.55
TT/AT 97 1 – –
AA 3 1.64 0.49
0.4 – 
6.9
AA 3 1.53 0.56
0.37 – 
6.35
AT/AA 28 1.37 0.3
0.74 – 
2.53
rs 11133360 VEGFR-2 TT 30 1 – – TT 30 1 – –
CT 50 0.72 0.3 0.38 – 
1.35
TT/CT 80 1 – –
CC 20 0.9 0.78 0.44 – 
1.85
CC 20 1.12 0.69 0.62 – 
2.04
CT/CC 70 0.77 0.4 0.43 – 
1.4
rs 3751143 P2X7R AA 60 1 – – AA 60 1 – –
AC 30 0.68 0.19
0.38 – 
1.22
AA/AC 90 1 – –
CC 10 0.66 0.48 0.2 – 
2.15
CC 10 0.75 0.64 0.23 – 
2.4
AC/CC 40 0.68 0.16
0.39 – 
1.17
rs 208294 P2X7R CC 29 1 – – CC 29 1 – –
CT 48 1.16 0.64 0.62 – 
2.19
CC/CT 77 1 – –
TT 23 1.1 0,8 0.49 – 
2.49
TT 23 1.001 0.99 0.5 – 
1.99
CT/TT 71 1.14 0.65 0.62 – 
2.1
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tumors are characterized by increased proliferation, 
reduced apoptosis, and a more developed vascular network 
that control tumors and by elevated secreted amounts of 
VEGF [40]. The growth and neoangiogenesis of P2X
7
R-
expressing tumors was blocked by intratumoral injection of 
the VEGF-blocking antibody bevacizumab, pharmacologic 
P2X
7
R blockade, or P2X7R silencing in vivo [40]. Recently, 
Amoroso and colleagues showed that P2X
7
R down-
modulation caused a reduction in HIF1alpha levels and 
VEGF secretion with a decreased vessel formation in a 
neuroblastoma model [41]. Based on these premises, it is 
conceivable to hypothesize that, in patients carrying the 
more unfavorable genetic profile, the pro-inflammatory 
activity and the tumor angiogenesis is sustained by the 
gene-gene interaction of both receptors, with a graduality 
due to the various combinations of genotypes, resulting in 
a worse prognosis. Such angiogenic phenotype could be 
due to an increase of the VEGF production attributable to 
an enhanced P2X
7
R activity, which may in turn activate 
an upregulated VEGFR-2. Unfortunately, the phenotypes 
corresponding to the VEGFR-2 rs11133360 genotypes are 
still unknown [42]. Therefore, it might be plausible that 
the genetic background may be responsible, in part, for 
the prognosis in these metastatic prostate cancer patients. 
Conversely, in patients with a more favorable genetic 
profile, the microenvironment conditions due to the different 
genotype combinations may result in a reduction of the 
VEGF production and in the presence of fewer VEGFR-2, 
or of its lower activity, on tumor endothelial cells which are 
not capable to proliferate, migrate or survive.
Thus, despite the objective difficulties to demonstrate a 
biological mechanism for the statistically demonstrated gene-
gene interaction, our original findings may provide a new 
reliable prognostic value and suggest previously unknown 
hypotheses for further testing also biological epistatic 
interactions. Although this study presents some strengths as 
the long observational follow-up of the patients, lasting almost 
20 years, or the extreme novelty of the approach, however, 
final considerations are restricted by the exploratory nature 
of its retrospective design, the limited sample size with the 
potential risk of an over-estimation of the obtained results. 
Indeed, these results should be only considered as “hypothesis 
generating” and only a well-designed prospective clinical 
trial may eventually confirm the suggested innovative role 
of the genetic interaction profile between specific VEGFR-2 
(rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) 
genotypes analyzed by SDR. However, understanding 
the reasons why the singular genotypes of both VEGFR-2 
rs2071559 and rs11133360 or P2X7R rs3751143 and rs208294 
were not associated to the greater benefit in terms of OS in 
our study, in contrast to what reported when combined in the 
interaction analysis, remains a challenge.
The identification of good versus poor prognosis 
prostate cancer patients through non-invasive and reliable 
means is a largely unmet clinical need. The possible 
clinical implication of identifying a favorable and an 
unfavorable group through SDR analysis could reside 
on this characteristic. In fact, we could hypothesize that 
poor prognosis patients may benefit from novel treatment 
strategies from the very beginning, and perhaps should be 
considered earlier for clinical trials with innovative drugs 
rather than waiting until the failure of standard therapies. 
On the other hand, prostate cancer patients with overall 
good prognosis may opt for a less aggressive treatment 
among the available standard therapeutic options.
In conclusion, the SDR methodology has been applied 
in these unselected prostate cancer patients to investigate the 
role of an interaction between VEGFR-2 and P2X7R gene 
polymorphisms in identifying a genetic profile associated 
with the greater probability of OS. The results have confirmed 
the relevance of SDR analyses, as already described by other 
authors, suggesting a more rational approach when SNPs are 
investigated as possible predictors of prognosis.
MATERIALS AND METHODS
Study population
The present multicenter, retrospective, genetic study 
was approved by the local ethics committee. Patients 
Table 5: Survival dimensionality reduction (SDR) model for the survival analysis of dataset
IBS
n-way SNPs (genes) in each dimension Training Testing p
1 rs3751143 (P2X7R) 0.1876 0.1877
2 rs1870377 (VEGFR-2), rs3751143 (P2X7R) 0.1846 0.1852
3
rs11133360 (VEGFR-2), rs3751143 (P2X7R), rs208294 
(P2X7R)
0.1741 0.1784 <0.001
4
rs2071559 (VEGFR-2), rs11133360 (VEGFR-2), rs3751143 
(P2X7R), rs208294 (P2X7R)
0.1638 0.1689 <0.001
Selection of the best combination of attributes by the SDR method. The model with the minimum testing Integrated Brier 
Score (IBS) value in the cross-validated testing sets is indicated in boldface type. P values associated with the log-rank test 
statistic calculated by the 1000-fold permutation test. SNP, single nucleotide polymorphism.
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were informed of the investigational nature of the study 
and provided their written informed consent for collecting 
genetic data. One-hundred patients with age ≥ 18 years and 
histological diagnosis of prostate adenocarcinoma were 
enrolled (Table 1), and they were assessed for the present 
genetic study. Other inclusion criteria were PSA ≥ 10 ng/
mL; Eastern Cooperative Oncology Group performance 
status (ECOG PS) of ≤ 2; adequate bone marrow function 
(leukocytes, ≥ 3000/mL; neutrophil count, ≥ 1500/mL; 
hemoglobin level, ≥ 10 g/dL; platelets, ≥ 100,000/mL); 
adequate liver function (total serum bilirubin level, < 1.5 mg/
dl; aspartate aminotransferase and alanine aminotransferase, 
< 3-fold upper limit of normal); adequate renal function 
(serum creatinine level, < 1.5 mg/dL), and life expectancy 
≥ 3 months. Exclusion criteria at baseline were acute 
cardiovascular disease (uncontrolled hypertension and 
arrhythmia; myocardial infarction within 2 years before 
enrolment; unstable angina; New York Heart Association, 
grade II or greater congestive heart failure), active infections, 
high risk of thromboembolic events without prophylactic 
treatments, untreated hemorrhagic gastric disease, or 
presence of brain metastases. Sites of metastatic disease 
were evaluated by radiological exams (radiography, X-ray 
computed tomography) and ultrasonography (Table 1).
At the enrollment, clinical evaluations included: 
patient’s medical history; a physical exam with an 
assessment of weight, vital signs, and ECOG PS; 
electrocardiogram plus cardiovascular examinations; 
Table 6: Results of the genetic interaction analysis to translate the genotype combinations of the 
VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes into favorable or 
unfavorable genetic profiles for overall survival
Favorable genetic profile Unfavorable genetic profile
rs2071559 rs11133360 rs3751143 rs208294 rs2071559 rs11133360 rs3751143 rs208294
AA CC AA CC AA CC AA CT
AA CC AA TT AA CC AC CT
AA CC CC CT AA CT AA TT
AA CT AA CC AA CT AC CC
AA CT AA CT AG CC AA CC
AA CT AC CT AG CC AA CT
AA CT AC TT AG CT AA CT
AA TT AA CC AG CT AC TT
AA TT AC CT AG TT AA CC
AA TT AC TT AG TT AC CT
AG CC AC CT AG TT AC TT
AG CC AC TT GG CC CC TT
AG CT AA CC GG CT AA TT
AG CT AA TT GG CT AC CC
AG CT AC CC GG TT AA CC
AG CT AC CT GG TT AA CT
AG TT AA CT
AG TT CC CT
AG TT CC TT
GG CC AC CT
GG CT AA CC
GG CT AA CT
GG CT CC CC
GG CT CC TT
GG TT AC CT
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complete blood count; complete serum biochemistry (i.e., 
serum creatinine, fasting glucose, sodium, potassium, 
calcium, lactate dehydrogenase, aspartate aminotransferase, 
alanine aminotransferase, γGT, ALP, total bilirubin, PT, 
aPTT, fibrinogen, and D-dimer), PSA serum levels.
SNP selection
The SNPs included in our study (Table 3) were 
selected on the basis of three main considerations: (i) thus 
far no genetic interaction analysis has been reported between 
the chosen SNPs and prognosis of prostate cancer, and 
possible gene-gene interactions could determine previously 
undescribed statistical epistatic effects; (ii) some of the SNPs 
have been significantly associated with risk or prognosis in 
other tumour types [23, 26, 43–47]; (iii) some SNPs have 
been associated with a modulation of the gene expression, or 
with impaired activity of the receptors [10–12, 48]. Although 
for some of chosen SNPs the phenotypic effects are still 
undefined or controversial, we decided to include them in our 
research because of the possibility that gene-gene interaction 
could produce an unexpected statistical epistatic effect.
Genotyping analyses
Blood samples (3 ml) were collected in EDTA tubes 
and stored at -80°C. P2X7R and VEGFR-2 genes and 
polymorphisms of Table 3 were chosen for the present 
analyses. Germline DNA extraction was performed using 
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA). 
Allelic discrimination of genes was performed using an ABI 
PRISM 7900 SDS (Applied Biosystems, Carlsbad, CA, 
USA) and with validated TaqMan® SNP genotyping assays 
(Table 3; Applied Biosystems). PCR reactions were carried 
out according to the manufacturer’s protocol. Genotyping 
was not performed until an adequate number of events (>80% 
on study population) was reported in terms of OS.
Statistical analysis
All polymorphisms were analyzed for deviation 
from the Hardy-Weinberg Equilibrium (HWE), through 
comparison between observed allelic distributions with 
those expected from the HWE by on χ2 test. Linkage 
disequilibrium (LD) between markers in VEGFR-2 
(n = 4) and P2X7R (n = 2) was analysed using Haploview 
Table 7: Multivariate Cox regression model
Variables HR p 95%CI
Age 0.93 0.008 0.88 – 0.98
ECOG PS 1.40 0.34 0.7 – 2.8
Gleason Score 5.18 0.005 1.65 – 16.2
Genetic profile
Unfavorable 1 – –
Favorable 0.29 0.0001 0.15 – 0.56
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval; ECOG PS was 
analysed as continuous variable. Gleason Score represents the risk difference between patients with <7 (reference) and ≥7.
Figure 1: Overall survival curve of all patients (A), and overall survival curves according to the favorable and 
unfavorable genetic profiles (B). Survival curves were calculated by the Kaplan Meier method. CI, confidence interval.
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software package [49]. The association between each 
individual polymorphism and the most relevant clinical-
pathological characteristics with overall survival (OS) 
was tested using a Cox proportional hazards model. OS 
were calculated from the date of the diagnosis to the date 
of death/lost to follow-up.
PHASE software v 2.1 [50] was used to perform 
haplotype analysis for VEGFR-2 and P2X7R regions 
separately. Only common haplotypes with a frequency 
≥ 5% were included in COX survival analysis. Most 
common haplotype was used as the reference and were 
provided hazard ratios (HR) for a given haplotype relative 
to reference haplotype.
The Survival Dimensionality Reduction (SDR) 
methodology was applied (using version 2.0a of SDR 
software available on http://sourceforge.net/projects/
sdrproject/) to detect non-linear gene-gene interactions in 
presence of right-censored data in identifying biomarkers 
of prognosis in OS [18]. The best combination of SDR 
model was chosen based on the lowest testing Integrated 
Brier Score (IBS) value. Log-rank test statistic calculated 
by the 100-fold permutation test was used to evaluate 
association and model efficiency.
The genotype combination with the OS benefit 
and improvement was used for further analyses. The 
difference in OS between favorable genetic profiles 
and the unfavorable genetic profiles were assessed 
with the log-rank test and the Kaplan-Meier method 
to evaluate survival curves. A Cox proportional 
hazards model, with the possible genetic profiles and 
the clinical and pathological patient characteristics 
individually correlated with the OS, was used to 
calculate the adjusted hazards ratio (HR) and the 95% 
confidence interval (95% CI). In these analyses we 
used Bonferroni’s correction and the p value < 0.0083 
(0.05/6 SNPs = 0.0083) was accepted as statistically 
significant. The Kaplan–Meier and Cox proportional 
hazards analyses were performed using the STATA 
package version 11.0 (StataCorp).
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